CMCSA vs BMY โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BMY Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Bristol-Myers Squibb Co. (BMY) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CMCSA counters with relative strength in Valuation. Fundamentally, CMCSA trades at 7.1x Forward P/E with 14.7% operating margin (-6.1% YoY revenue) versus BMY at 8.8x Forward P/E and 32.4% operating margin (+6.9% YoY). In options structure, CMCSA sits in CONSOLIDATION (30th %ile IV; Dealer Gamma Walls on Pro) against BMY sits in CONSOLIDATION (24th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CMCSA Revenue | BMY Revenue | CMCSA Op. Margin | BMY Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $94.5B | $22.6B | 20.1% | 21.8% | BMY |
| FY2019 | $108.9B | $26.1B | 19.4% | 13.2% | CMCSA |
| FY2020 | $103.6B | $42.5B | 16.9% | -21.2% | CMCSA |
| FY2021 | $116.4B | $46.4B | 17.9% | 15.1% | CMCSA |
| FY2022 | $121.4B | $46.2B | 11.6% | 13.7% | BMY |
| FY2023 | $121.6B | $45.0B | 19.2% | 17.8% | CMCSA |
| FY2024 | $123.7B | $48.3B | 18.8% | -18.5% | CMCSA |
| FY2025 | $123.7B | $48.2B | 16.7% | 14.6% | CMCSA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CMCSA | BMY | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $88.3B | $119.3B | Larger Scale | BMY |
| Trailing P/E Ratio Valuation | 7.9x | 12.9x | Lower Multiple | CMCSA |
| Forward P/E Ratio Valuation | 7.1x | 8.8x | Lower Multiple | CMCSA |
| Revenue Growth (YoY) Growth | -6.1% | +6.9% | Higher Growth | BMY |
| Operating Margin (TTM) Profitability | 14.7% | 32.4% | Higher Margin | BMY |
| Net Profit Margin Profitability | 9.2% | 18.5% | Higher Margin | BMY |
| Return on Equity (ROE) Capital Efficiency | 11.4% | 44.0% | Higher ROE | BMY |
| 52-Week Range Position Momentum | 36% ($20โ$33) | 58% ($45โ$69) | Stronger Trend | BMY |
| Beta / 30D Volatility Risk Regime | -0.01ฮฒ ยท 32% Vol | 0.16ฮฒ ยท 28% Vol | Lower Realized Risk | BMY |
| Unified Institutional Score Composite Signal | 32.8 / 100 (SELL) | 48.9 / 100 (HOLD) | Higher Composite | BMY |